Other baseline characteristics, including age, gender, tumor ulceration, BRAF mutation status, mitotic index, melanoma location, anti–PD-1 type and steroid use, did not differ significantly between the two groups (Table 3). This evidence concerns the gene PDCD1 and melanoma.